Obesity and diabetes as accelerators of functional decline: can lifestyle interventions maintain functional status in high risk older adults
I don't snack at night anymore and my pants actually button comfortably again
doi: 10.1111/cns.13694 33 WangZYHanQQDengMYZhaoMJApryaniEShoaibRMet al
This test analyzes genetic variants in key pathwaysincluding the GLP1R and GIPR genesthat influence how your body responds to GLP-1 therapies
Orlistat, phentermine/topiramate, naltrexone/bupropion, and the incretin-based drugs liraglutide and semaglutide, both GLP-1 receptor agonists (GLP-1RA), and tirzepatide, a biased dual GIP/GLP-1 receptor agonist, are currently both FDA and EMA approved for the management of non-syndromic obesity 10
Presented at the 39th Annual Meeting of The Obesity Society (TOS) held at ObesityWeek, virtual meeting